IP Library Granted Patent US 11,571,531
Granted Patent B2
US 11,571,531 · App. 15/879,009 · Granted Feb 7, 2023

Powder delivery devices

Inventors: Per Gisle Djupesland (Oslo, NO); Roderick Peter Hafner (Wiltshire, GB); Colin David Sheldrake (Wiltshire, GB)
Assignee: OptiNose Inc.
A61M15/08A61M15/003A61M15/0021A61M15/0028A61M15/0035A61M15/0041A61M15/0086A61M15/0098A61M16/0066A61M16/105A61M16/127A61M16/1075A61M2016/0021A61M2016/0027A61M2202/064A61M2205/07A61M2205/076A61M2205/3606A61M2205/3673A61M2205/8218A61M2206/14A61M2210/0618A61M2210/0625
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,571,531
App. No.
15/879,009
Granted
Feb 7, 2023
Kind
B2
Abstract

A nasal delivery device for delivering substance to a nasal cavity of a subject, the delivery device comprising: a substance supply unit for supplying a dose of substance to be delivered to the nasal cavity of the subject, the substance supply unit including an inlet and an outlet; a nosepiece unit including a nosepiece for fitting to a nasal cavity of the subject and being in fluid communication with the outlet of the substance supply unit; and a mouthpiece unit including a mouthpiece in fluid communication with the inlet of the substance supply unit and through which the subject in use exhales such as to entrain substance from the container chamber and deliver the same through the nosepiece, and at least one temperature modifier for reducing a temperature of the exhaled air flow such as to reduce the absolute humidity thereof.

Claims (21)

1. A method of delivering powdered substance to a nasal cavity of a subject, the method comprising:

rupturing a powdered substance-containing container within a substance supply unit of a delivery device, wherein the delivery device comprises:

the substance supply unit for supplying a dose of powdered substance to be delivered to the nasal cavity of the subject, the substance supply unit including an inlet and an outlet;

a nosepiece unit including a nosepiece for fitting to the nasal cavity of the subject and being in fluid communication with the outlet of the substance supply unit; and

a mouthpiece unit including a mouthpiece in fluid communication with the inlet of the substance supply unit and through which the subject in use exhales such as to entrain powdered substance from the substance supply unit and deliver the same through the nosepiece;

wherein the substance supply unit comprises a container chamber for receiving the powdered substance-containing container which contains a dose of powdered substance, and the container or an outer coating on a body of the container is formed of a material which exhibits insufficient tackiness in the presence of moisture so as not to adhere to an inner surface of the container chamber during emptying of the powdered substance from the container;

fitting the nosepiece unit of the delivery device to the nasal cavity of the subject; and

the subject exhaling through the mouthpiece unit such as to entrain powdered substance from the substance supply unit and deliver the same through the nosepiece to the nasal cavity of the subject.

2. The method of claim 1 , wherein the container chamber is substantially cylindrical in shape or substantially spherical in shape.

3. The method of claim 1 , wherein the substance supply unit comprises a rupturing mechanism for rupturing the container as contained in the container chamber.

4. The method of claim 1 , wherein the container or the outer coating of the container is formed of a material which exhibits insufficient tackiness in the presence of moisture in the exhalation air flow for a period of (i) up to about 5 s following exhalation, (ii) up to about 2 s following exhalation, or (iii) up to about 1 s following exhalation.

5. The method of claim 4 , wherein the container or the body of the container is formed substantially of a cellulose derivative, optionally one or more of hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose, methylcellulose, ethylcellulose and carboxymethylcellulose.

6. The method of claim 4 , wherein the coating comprises substantially one of parylene, hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, polyvinyl alcohol, acrylic acid polymer, methacrylic acid polymer, ethyl acrylic acid polymer, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and hydroxyl methylcellulose acetate succinate, or any combination of layers thereof.

7. The method of claim 1 , wherein the container comprises a capsule, optionally the capsule is substantially cylindrical in shape or substantially spherical in shape.

8. The method of claim 1 , wherein the powdered substance is a hygroscopic powder.

9. The method of claim 1 , wherein the container or the body of the container comprises a cellulose derivative.

10. The method of claim 1 , wherein the container or the body of the container comprises hydroxypropyl methylcellulose (HPMC).

11. The method of claim 1 , wherein the container or the body of the container comprises one or more of hydroxypropylcellulose, methylcellulose, ethylcellulose and carboxymethylcellulose.

12. The method of claim 1 , wherein the container or the body of the container comprises methylcellulose.

13. The method of claim 1 , wherein the container or the body of the container comprises ethylcellulose.

14. The method of claim 1 , wherein the container or the body of the container comprises carboxymethylcellulose.

Assignments (6)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 71337/0132 Recorded Mar 17, 2026
From: OAKTREE FUND ADMINISTRATION, LLC
To: OPTINOSE, INC.
Reel/Frame 075101/0804 →
SECURITY INTEREST Recorded May 22, 2025
From: OPTINOSE, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071337/0132 →
RELEASE OF SECURITY INTEREST Recorded May 21, 2025
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: OPTINOSE INC.
Reel/Frame 071547/0979 →
CHANGE OF ADDRESS Recorded Jan 2, 2025
From: OPTINOSE, INC.
To: OPTINOSE, INC.
Reel/Frame 069810/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: OPTINOSE AS
To: OPTINOSE INC
Reel/Frame 061546/0424 →
SECURITY INTEREST Recorded Sep 13, 2019
From: OPTINOSE AS
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 050371/0913 →
Priority Claims (1)
GB 0503738 · Feb 23, 2005 · national
Continuity (4)
Division 14829845 · Aug 19, 2015
Continuation 14491720 · Sep 19, 2014
Continuation 11816984
Related Publication 20180272085A1 · Sep 27, 2018